source
- Roche commits over $1 billion to DualityBio for ADC development targeting TOP1 resistanceRoche's Genentech unit announced a major investment in DualityBio to advance antibody-drug conjugate (ADC) technology. Under the agreement DualityBio will receive an upfront payment of $45 million…
- Cytokinetics aims for broader Myqorzo approval next year after supportive trial dataCytokinetics reported new data on its cardiac therapy Myqorzo, presented at a European scientific meeting. The results reinforce the drug’s efficacy in a specific heart muscle disorder. The compan…